178 related articles for article (PubMed ID: 36861447)
1. Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.
Chen Y; Wang X; Du F; Yue J; Si Y; Zhao X; Cui L; Zhang B; Bei T; Xu B; Yuan P
Cancer Biol Med; 2023 Mar; 20(2):155-68. PubMed ID: 36861447
[TBL] [Abstract][Full Text] [Related]
2. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
3. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Llop-Guevara A; Loibl S; Villacampa G; Vladimirova V; Schneeweiss A; Karn T; Zahm DM; Herencia-Ropero A; Jank P; van Mackelenbergh M; Fasching PA; Marmé F; Stickeler E; Schem C; Dienstmann R; Florian S; Nekljudova V; Balmaña J; Hahnen E; Denkert C; Serra V
Ann Oncol; 2021 Dec; 32(12):1590-1596. PubMed ID: 34520831
[TBL] [Abstract][Full Text] [Related]
4. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
[TBL] [Abstract][Full Text] [Related]
5. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
[TBL] [Abstract][Full Text] [Related]
6. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
[TBL] [Abstract][Full Text] [Related]
7. Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
Chai Y; Chen Y; Zhang D; Wei Y; Li Z; Li Q; Xu B
J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207810
[TBL] [Abstract][Full Text] [Related]
8. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
[TBL] [Abstract][Full Text] [Related]
9. Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and
Telli ML; Chu C; Badve SS; Vinayak S; Silver DP; Isakoff SJ; Kaklamani V; Gradishar W; Stearns V; Connolly RM; Ford JM; Gruber JJ; Adams S; Garber J; Tung N; Neff C; Bernhisel R; Timms KM; Richardson AL
Clin Cancer Res; 2020 Jun; 26(11):2704-2710. PubMed ID: 31796517
[TBL] [Abstract][Full Text] [Related]
10. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
11. Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
Zhang L; Wu Z; Li J; Zhu D; Yang L; Shao Y; Lin Y; Liu Z; Cao Y; Zhang G; Shang S; Zhang Y; Wang K
JCO Precis Oncol; 2023 Jan; 7():e2200337. PubMed ID: 36652665
[TBL] [Abstract][Full Text] [Related]
12. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency derived from whole-genome sequencing predicts platinum response in triple-negative breast cancers.
Ter Brugge P; Moser SC; Bièche I; Kristel P; Ibadioune S; Eeckhoutte A; de Bruijn R; van der Burg E; Lutz C; Annunziato S; de Ruiter J; Masliah Planchon J; Vacher S; Courtois L; El-Botty R; Dahmani A; Montaudon E; Morisset L; Sourd L; Huguet L; Derrien H; Nemati F; Chateau-Joubert S; Larcher T; Salomon A; Decaudin D; Reyal F; Coussy F; Popova T; Wesseling J; Stern MH; Jonkers J; Marangoni E
Nat Commun; 2023 Apr; 14(1):1958. PubMed ID: 37029129
[TBL] [Abstract][Full Text] [Related]
14. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
15. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Mayer EL; Abramson V; Jankowitz R; Falkson C; Marcom PK; Traina T; Carey L; Rimawi M; Specht J; Miller K; Stearns V; Tung N; Perou C; Richardson AL; Componeschi K; Trippa L; Tan-Wasielewski Z; Timms K; Krop I; Wolff AC; Winer EP
Ann Oncol; 2020 Nov; 31(11):1518-1525. PubMed ID: 32798689
[TBL] [Abstract][Full Text] [Related]
16. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
[TBL] [Abstract][Full Text] [Related]
17. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
[TBL] [Abstract][Full Text] [Related]
18. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
[TBL] [Abstract][Full Text] [Related]
19. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy.
Jin J; Zhang W; Ji W; Yang F; Guan X
Cancer Biol Ther; 2017 Jun; 18(6):369-378. PubMed ID: 28494179
[TBL] [Abstract][Full Text] [Related]
20. Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
Lenz L; Neff C; Solimeno C; Cogan ES; Abramson VG; Boughey JC; Falkson C; Goetz MP; Ford JM; Gradishar WJ; Jankowitz RC; Kaklamani VG; Marcom PK; Richardson AL; Storniolo AM; Tung NM; Vinayak S; Hodgson DR; Lai Z; Dearden S; Hennessy BT; Mayer EL; Mills GB; Slavin TP; Gutin A; Connolly RM; Telli ML; Stearns V; Lanchbury JS; Timms KM
Breast Cancer Res Treat; 2023 Nov; 202(1):191-201. PubMed ID: 37589839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
